Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know
Avita Medical Inc. (RCEL) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's stock price, as changes in earnings potential are strongly correlated with near-term stock movements. The Zacks Rank system, which analyzes earnings estimate revisions, has a strong track record of identifying stocks poised for market-beating returns.
Avita Medical (NASDAQ:RCEL) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital has reiterated a "Buy" rating for Avita Medical (NASDAQ:RCEL) with a $10 price target, suggesting a significant upside of 140.38% from its previous closing price. This rating comes amidst a mixed analyst consensus of "Hold" with an average price target of $5.50. Despite varying ratings from other firms, Avita Medical's stock jumped 11.8% on Tuesday, and the company has attracted attention from several institutional investors.
RCEL: D. Boral Capital Maintains "Buy" Rating and $10 PT | RCEL Stock News
D. Boral Capital has reaffirmed its "Buy" rating for AVITA Medical (RCEL) with a maintained price target of $10, demonstrating consistent confidence in the company's performance. This re-evaluation by analyst Jason Kolbert aligns with previous assessments and reflects a positive outlook despite some varied ratings from other analysts. AVITA Medical, primarily known for its RECELL system for burn treatment, is forecasted to have an average target price of $6.20 by Wall Street analysts, suggesting a significant upside from its current price.
Avita Medical Earnings Call Signals Stabilizing Growth
Avita Medical's Q4 earnings call presented a picture of stabilization and execution discipline rather than rapid growth for 2025, with management focusing on steady revenue expansion, cost control, and a de-risked balance sheet. The company reported full-year 2025 revenue of $71.6 million, an 11% increase, and has guided 2026 revenue to a range of $80.0–$85.0 million, assuming normalization of ReCell utilization and contributions from new products. Despite high gross margins and improved cash burn, the company remains structurally unprofitable, with Q4 revenue softness and ongoing reimbursement challenges impacting profitability.
Avita Medical (RCEL) TTM US$48.6m Loss Tests Bullish Profitability Narratives
Avita Medical (RCEL) reported a Q4 revenue of US$17.6 million and a basic EPS loss of US$0.38, culminating in a full-year net loss of US$48.6 million for FY 2025. Despite analysts forecasting significant revenue and earnings growth, the company faces challenges including widening losses, negative equity, and a short cash runway, raising concerns about its financial stability. The stock trades at a low price-to-sales ratio compared to industry averages, which bulls see as an opportunity, but financial risks temper this optimism.
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (ASX: AVH, NASDAQ: RCEL) announced an investor webinar briefing set for February 18, 2026, at 2:00 p.m. Pacific Standard Time, covering financial and business results from its recent fourth-quarter and full-year 2025 earnings. Interim CEO Cary Vance and CFO David O'Toole will lead the presentation, which will include a Q&A session. A replay will be available on the company's website.
Avita's Road to Profitability Is in Sight
Avita Medical is expected to achieve profitability, driven by the strong performance and competitive advantages of its RECELL product. RECELL, a "spray-on skin" treatment, offers clinical effectiveness, ease of use, and a favorable price point compared to traditional skin grafts, posing a challenge to the current standard of care for larger burns. The company has also secured a new debt facility to further de-risk its path to positive cash flow.
Ask AVITA Medical’s interim CEO your questions in Feb. 18 investor webinar Q&A
AVITA Medical (NASDAQ: RCEL) will host an investor webinar on February 18, 2026, featuring Interim CEO Cary Vance and CFO David O'Toole. They will discuss the company's fourth-quarter and full-year 2025 financial and business results, followed by a Q&A session where participants can submit questions beforehand. The announcement led to a positive market reaction, with RCEL's stock gaining 11.29%.
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 Earnings Call Transcript
AVITA Medical (NASDAQ:RCEL) reported Q4 and full-year 2025 earnings, with Q4 revenue of $17.6 million and full-year revenue of $71.6 million, exceeding expectations for EPS. The company emphasized a new focus on disciplined execution and commercial refinement, overcoming reimbursement uncertainties that affected 2025. They provided 2026 revenue guidance of $80-85 million, driven by increased utilization of their ReCell, CoHiliX, and PermeDerm products within existing accounts.
Avita Medical (NASDAQ:RCEL) Issues Earnings Results, Misses Expectations By $0.02 EPS
Avita Medical (NASDAQ:RCEL) announced its quarterly earnings, reporting a ($0.38) EPS, missing analyst expectations by $0.02. Following the news, the stock declined by approximately 3.4% to $3.71. Analyst sentiment remains mixed, with an average "Hold" rating and institutional investors holding about 27.66% of the stock.
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
AVITA Medical (NASDAQ: RCEL, ASX: AVH) reported its Q4 and full-year 2025 financial results, showing total revenue of $17.6 million for Q4 and $71.6 million for the full year, an 11% increase from 2024. The company reduced operating expenses and improved cash efficiency, with a net loss of $48.6 million for the year. AVITA Medical also refinanced its debt under a new credit facility with Perceptive Advisors LLC, securing up to $60 million to support long-term growth and entering 2026 with a focus on execution-led growth.
AVITA Medical (RCEL) Q4 2025 Earnings Transcript
AVITA Medical (RCEL) reported Q4 2025 revenue of $17.6 million and full-year revenue of $71.6 million, an 11% annual increase, in line with guidance. The company achieved significant operational improvements, including reduced operating expenses and improved cash efficiency, positioning it for execution-driven growth in 2026. Key advancements include resolved reimbursement clarity for its ReCell product, expanded multi-product adoption, and a new credit facility that reduces covenant risk.
AVITA Medical, Inc. SEC 10-K Report
AVITA Medical, Inc. has released its annual 10-K report, detailing an 11% increase in total revenues to $71.6 million and a 21% decrease in net loss to $48.6 million. The company expanded its product portfolio with PermeaDerm and Cohealyx, received several FDA and CE mark approvals for its RECELL technology, and is focusing on increasing market penetration and achieving long-term profitability despite facing significant competitive, financial, and regulatory risks.
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
AVITA Medical announced its financial results for the fourth quarter and full year ended December 31, 2025, showing fourth-quarter revenue of $17.8 million and full-year revenue of approximately $60.8 million. The company reported continued progress in cash efficiency and reduced operating expenses, along with the refinancing of its debt with a new credit facility. AVITA Medical remains focused on disciplined cash management, sharp execution, and accelerating commercial momentum in its core U.S. burn and trauma markets for 2026.
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating
Lake Street has increased its price target for AVITA Medical, Inc. (RCEL) to $3.50 from $3 while maintaining a Hold rating. This decision follows the company's recent debt refinancing, which helped alleviate short-term liquidity concerns. AVITA Medical is projecting FY26 revenue of $80 million to $85 million, up from $71.6 million in FY24, and aims for execution-led growth after strengthening its financial foundation and clinical pipeline.
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating
Lake Street has increased its price target on AVITA Medical, Inc. (RCEL) to $3.50 from $3 while keeping a Hold rating, attributing the change to the company's recent debt refinancing which eased liquidity concerns. The firm is awaiting Q4 results and clearer reimbursement trend commentary before taking a more positive stance. AVITA Medical projects FY26 revenue of $80 million to $85 million, emphasizing a transition to execution-led growth following efforts to stabilize revenue and improve financial flexibility.
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating
Lake Street has increased its price target for AVITA Medical, Inc. (RCEL) to $3.50 from $3.00, while reiterating a Hold rating. This adjustment follows the company's recent debt refinancing, which has eased short-term liquidity concerns. The firm awaits Q4 results and clarity on reimbursement trends for a more optimistic outlook.
Avita Medical (RCEL) to Release Quarterly Earnings on Thursday
Avita Medical (RCEL) is set to release its Q4 2025 earnings before market open on Thursday, February 12th, with analysts forecasting an EPS of ($0.36) and revenue of $26.27 million. The company missed estimates in the prior quarter and analysts expect a full-year EPS of -$1, improving to $0 for the next fiscal year. RCEL stock recently traded at $4.08, down 5.1%, and currently holds an average "Hold" rating from analysts with a mean price target of $5.50.
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Rating of "Hold" from Brokerages
Five analysts currently rate Avita Medical (NASDAQ:RCEL) with a "Hold" consensus, with an average 12-month price target of $5.50, despite some divergent opinions including a $10.00 buy target from D. Boral Capital. The company recently missed quarterly earnings expectations, reporting ($0.46) EPS against a ($0.43) forecast and $17.06 million in revenue compared to an expected $29.39 million. Avita Medical, a regenerative medicine company focused on cell-based therapies, had an opening stock price of $4.41 and a market capitalization of $134.46 million.
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
AVITA Medical Inc. (ASX: AVH, NASDAQ: RCEL) presented 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the first integrated use of its RECELL, PermeaDerm, and Cohealyx technologies. The data highlights improved healing, reduced complications, and shorter hospital stays in burn and complex wound care, with new histological findings supporting PermeaDerm and Cohealyx for wound bed preparation. These presentations underscore the effectiveness and practical applications of AVITA Medical's advanced wound care solutions.
AVITA Medical (RCEL) Analyst Rating: Maintained 'Buy' with $10 PT
D. Boral Capital has reaffirmed its "Buy" rating for AVITA Medical (RCEL) and maintained a $10 price target, with analyst Jason Kolbert making no changes from his previous recommendation. This aligns with other recent analyst ratings, including a "Hold" from Lake Street with a raised price target to $3.50, and earlier adjustments by D. Boral Capital and BTIG. AVITA Medical, known for its RECELL system, is primarily focusing on the US market for its burn treatment device, despite having product approval in several other countries.
D. Boral Capital Reaffirms Buy Rating for Avita Medical (NASDAQ:RCEL)
D. Boral Capital has reissued a "Buy" rating for Avita Medical (NASDAQ:RCEL), setting a price target of $10.00, which suggests a potential upside of 125.23%. This rating contrasts with the broader analyst consensus of "Hold" and an average price target of $5.50. The company recently missed its quarterly EPS and revenue estimates, and institutional investors own 27.66% of its shares.
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
AVITA Medical announced data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the first surgeon-reported integrated use of its three technologies: RECELL, PermeaDerm, and Cohealyx. The presentations highlighted how combining these technologies benefits patients and facilities, while new clinical and tissue-level data further supported the effectiveness of PermeaDerm and Cohealyx in wound bed preparation. Additionally, analyses demonstrated RECELL's consistent trends in improving healing, reducing complications, and shortening hospital stays across various studies.
First three-part AVITA burn care path cuts painful dressing changes
AVITA Medical (NASDAQ: RCEL) presented data at the 2026 Boswick Burn & Wound Symposium, showcasing the first integrated use of their RECELL, PermeaDerm, and Cohealyx technologies in single care pathways for burn patients. The data highlights reduced hospital stays, faster healing, and fewer complications with RECELL, along with initial histological findings supporting PermeaDerm and Cohealyx for wound preparation. This integrated approach is significant for improving care, especially in challenging cases and rural settings, by reducing painful dressing changes and follow-up appointments.
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical's share price recently rose 26%, but its muted revenue growth and a 52% drop over the past year have kept its price-to-sales (P/S) ratio low. Analysts forecast significantly slower revenue growth for AVITA Medical compared to the broader biotech industry, contributing to investor reluctance to pay a higher premium for the stock. Despite a strong 127% revenue growth over the last three years, the company's future outlook suggests limited growth, justifying its subdued P/S ratio.
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical, Inc. (NASDAQ:RCEL) has seen a 26% share price increase recently, but its price-to-sales (P/S) ratio of 1.9x suggests muted revenue expectations compared to the Biotech industry average of 11.9x. Despite a 127% revenue growth over the last three years and 21% in the last year, analysts forecast a 43% annual revenue climb for AVITA Medical for the next three years, significantly lower than the industry's projected 132% growth, contributing to its low P/S ratio. The article concludes that investors are not optimistic enough about future revenue growth to justify a higher P/S, despite the recent stock rally.
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical Inc.'s share price recently rose by 26%, yet its price-to-sales (P/S) ratio remains low at 1.9x compared to an industry average of 11.9x. This subdued P/S ratio is attributed to expectations of continued muted revenue growth, despite a 127% revenue increase over the last three years. Analysts forecast a 43% annual revenue growth for AVITA Medical, significantly less attractive than the industry's projected 132% annual growth, leading investors to pay a reduced amount for the stock due to limited future growth expectations.
AVITA Medical, Inc.'s (NASDAQ:RCEL) Path To Profitability
AVITA Medical, Inc. (NASDAQ:RCEL) is nearing profitability, with analysts predicting the company will break even in 2027 by generating positive profits of $12 million. The company has reduced its losses from $62 million to $49 million but needs an optimistic average annual growth rate of 54% to meet this target. Investors should also note the company currently has negative equity on its balance sheet.
AVITA Medical, Inc.'s (NASDAQ:RCEL) Path To Profitability
AVITA Medical, Inc. (NASDAQ:RCEL) is nearing profitability, with analysts predicting it will break even by 2027, transitioning from a US$49m loss to a US$12m profit. This milestone requires an ambitious annual growth rate of 54%. Investors should note the company's current negative equity, which is a common but significant concern for biotechs reporting accumulated losses.
AVITA Medical (RCEL): Analyst Lowers Price Target, Maintains Buy Rating | RCEL Stock News
D. Boral Capital has maintained a Buy rating for AVITA Medical (RCEL) but lowered its price target from $14.00 to $10.00. This adjustment follows other recent analyst actions, including BTIG upgrading RCEL from Sell to Neutral and Lake Street downgrading it from Buy to Hold with a reduced price target. Despite the lowered target, the average analyst price target suggests a significant upside from the current stock price, and GuruFocus estimates an even greater potential upside based on its fair value calculations.
AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook
AVITA Medical announced preliminary financial results and a business update for Q4 and fiscal year 2025, ahead of its J.P. Morgan Healthcare Conference presentation. The company reported full-year 2025 revenues of $71.6 million, refinanced existing debt with a new $60 million credit facility from Perceptive Advisors, and projected 2026 revenues between $80 to $85 million. These announcements highlight the company's shift from stabilizing revenue to execution-led growth, supported by a strengthened balance sheet and clinical advancements.
Avita's Road to Profitability Is in Sight
Morningstar anticipates that Avita's RECELL product will significantly disrupt the standard treatment for larger burns due to its clinical effectiveness, ease of use, and competitive pricing. RECELL quickly creates "Spray-on Skin" from a small skin sample, healing burns without the large donor site wounds associated with traditional skin grafts. The company is expected to achieve profitability aided by a new debt facility that de-risks its financial runway.
Avita Medical Inc - Enters Into Credit Agreement And Guaranty - SEC Filing
Avita Medical Inc has entered into a credit agreement and guaranty, as detailed in an SEC filing. This information was reported via Reuters and is available on TradingView News Search, indicating a significant financial development for the company.
AVITA Medical Signs Credit Agreement and Guaranty With Perceptive Credit Holdings V
AVITA Medical has refinanced its capital structure by securing a new five-year senior secured credit facility of up to $60 million with Perceptive Credit Holdings V, simultaneously terminating its previous agreement with an OrbiMed Advisors affiliate. The company drew $50 million at closing and can access an additional $10 million by March 31, 2027, subject to a net revenue requirement. This financing package includes a security agreement, a warrant agreement (pending shareholder approval), and a fee letter, which management believes will improve liquidity and support ongoing operations.
AVITA Medical outlines $80–85M 2026 sales and new $60M credit deal
AVITA Medical (NASDAQ: RCEL) announced preliminary 2025 financial results, forecasting approximately $71.6 million in revenue, an 11% increase from 2024. The company has secured a new five-year credit facility of up to $60 million with Perceptive Advisors and projects 2026 revenues between $80-$85 million, representing 12%-19% growth. Additionally, AVITA Medical provided updates on its clinical trials, with Cohealyx-I fully enrolled and PermeaDerm-I over 75% enrolled, with data for both expected later in 2026.
AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook
AVITA Medical has provided a pre-J.P. Morgan update, announcing unaudited preliminary financial results for Q4 and full year 2025, and an outlook for fiscal year 2026. The company refinanced its existing debt with a new $60 million credit facility from Perceptive Advisors, strengthening its capital structure. They anticipate 2026 revenue to be between $80 and $85 million, representing 12% to 19% growth over 2025.
AVITA Medical reports Q4 revenue of $17.6 million, secures new debt
AVITA Medical reported preliminary unaudited Q4 2025 revenue of $17.6 million, a decrease from the prior year, but full-year 2025 revenue increased by 11% to $71.6 million. The company secured a new five-year $60 million credit facility from Perceptive Advisors to repay debt and support growth, projecting 2026 revenue between $80 million and $85 million. AVITA Medical also announced the appointment of Joe Woody as a non-executive Director, bringing extensive medical technology leadership experience to the board.
AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook
AVITA Medical has provided an unaudited preliminary financial and business update, including total net revenues of $17.6 million in Q4 2025 and $71.6 million for the full year 2025, an 11% increase from 2024. The company has also secured a new five-year credit facility for up to $60 million with Perceptive Advisors to refinance existing debt and support growth, with an initial $50 million already funded. AVITA Medical expects full-year 2026 revenue to be between $80 to $85 million, representing a 12% to 19% growth compared to 2025.
Joe Woody joins AVITA Medical board as Lou Panaccio retires By Investing.com
AVITA Medical, Inc. has announced the appointment of Joe Woody as a non-executive Director, succeeding Lou Panaccio, who retired after over a decade of service as Chairman. Woody brings extensive medical technology leadership experience from roles at Avanos Medical, Acelity Holdings, Covidien, and Smith & Nephew. AVITA Medical is a therapeutic acute wound care company known for its FDA-approved RECELL System.
Joe Woody joins AVITA Medical board as Lou Panaccio retires
AVITA Medical has announced the appointment of Joe Woody as a non-executive Director to its board and the retirement of Lou Panaccio, who previously served as Chairman for over a decade. Woody brings extensive medical technology leadership experience, having been CEO of Avanos Medical and Acelity Holdings, among other roles. Panaccio's retirement marks the end of his significant contributions to AVITA Medical's commercial and operational strategy as the company continues to focus on its acute wound care products like the RECELL System.
AVITA Medical Announces Changes to its Board of Directors
AVITA Medical has announced changes to its Board of Directors, appointing Joe Woody as a new non-executive Director and marking the retirement of Lou Panaccio after over a decade of service. Woody brings extensive leadership experience from global med-tech companies, which is expected to be invaluable as AVITA Medical continues its growth trajectory. The company expressed gratitude to Panaccio for his significant contributions and leadership.
Avita Medical Adds Veteran Director Amid Leadership Transition
AVITA Medical has appointed Joe Woody, a veteran med-tech executive, as a non-executive director, effective January 1, 2026, while longtime chairman Lou Panaccio retired. This move aims to strengthen the company's strategic and commercial expertise amidst its growth phase. Spark, TipRanks' AI Analyst, rates RCEL as "Underperform" due to significant financial challenges and a bearish technical outlook.
Joe Woody joins AVITA Medical board as Lou Panaccio retires By Investing.com
AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH) has appointed Joe Woody as a non-executive Director, while long-serving Chairman Lou Panaccio retires after a decade with the company. Woody brings over twenty years of medical technology leadership experience, including his recent tenure as CEO of Avanos Medical. This leadership change occurs as AVITA Medical approaches its next earnings release on February 9, 2026.
AVITA Medical Announces Changes to its Board of Directors
AVITA Medical has announced changes to its Board of Directors, appointing Joe Woody as a new non-executive Director and marking the retirement of Lou Panaccio after over a decade of service. Woody, a veteran healthcare executive, brings extensive experience in leading global med-tech companies. The company expressed gratitude to Panaccio for his contributions and looks forward to Woody's insights in scaling AVITA Medical's growth and value creation.
AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
AVITA Medical announced that its Chief Executive Officer, Cary Vance, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be available via a live audio webcast on the company's website. AVITA Medical specializes in acute wound care solutions, including the RECELL System for burn and trauma wounds.
How to listen to AVITA Medical's J.P. Morgan conference talk live
AVITA Medical (NASDAQ: RCEL) announced its CEO, Cary Vance, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 5:15 p.m. PT. A live audio webcast and subsequent replay will be available on the company's Investor Relations website. This event is part of AVITA's ongoing efforts to engage with the investment community, with past conference appearances showing mixed market reactions while investor webinars received positive responses.
AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
AVITA Medical (ASX: AVH, NASDAQ: RCEL) announced that its CEO, Cary Vance, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be webcast live and available for replay on the company's website. AVITA Medical specializes in transformative acute wound care solutions, notably with its RECELL System.
Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Recommendation of "Hold" by Analysts
Avita Medical Inc. (NASDAQ:RCEL) has received a consensus "Hold" rating from six analysts, with a mean 12-month price target of $10.50. The company recently missed earnings expectations, reporting an EPS of ($0.46) against an expected ($0.43) and revenue of $17.06 million versus $29.39 million. Shares are currently trading around $3.53, with institutional investors owning approximately 27.66% of the stock.
AVITA Medical to Present at the Piper Sandler 37?? Annual Healthcare Conference
AVITA Medical (ASX: AVH, NASDAQ: RCEL) announced it will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m. EST. Management will also be available for one-on-one meetings with registered investors. A live audio webcast will be available on the company's website, with a replay accessible after the event.
AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference
AVITA Medical will present at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 8:30 a.m. EST. Management will also be available for one-on-one meetings with registered investors. A live audio webcast and replay of the presentation will be accessible on AVITA Medical's website.
